ReviewTissue engineering. Part B, Reviews2010
High-content drug screening with engineered musculoskeletal tissues.
Review in Tissue engineering. Part B, Reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Cell alignment on novel polymeric micro-hollow fiber membranes for neural and musculoskeletal tissue engineering.Cell and tissue research · 2026Article
- A Micromanipulation-Actuated Large-Scale Screening to Identify Optimized Microphysiological Model Parameters in Skeletal Muscle Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A comprehensive review of animal models for cancer cachexia: Implications for translational research.Genes & diseases · 2024Review
- Review
- Review
- Adipogenic Differentiation Alters Properties of Vascularized Tissue-Engineered Skeletal Muscle.Tissue engineering. Part A · 2022Article
- Engineering Biological Tissues from the Bottom-Up: Recent Advances and Future Prospects.Micromachines · 2021Review
- A Pound of Flesh: What Cachexia Is and What It Is Not.Diagnostics (Basel, Switzerland) · 2021Review
- Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects.Journal of colloid and interface science · 2020Article
- A multiplexed in vitro assay system for evaluating human skeletal muscle functionality in response to drug treatment.Biotechnology and bioengineering · 2020Article
- Engineered skeletal muscles for disease modeling and drug discovery.Biomaterials · 2019Review
- Effect of Cyclic Stretch on Tissue Maturation in Myoblast-Laden Hydrogel Fibers.Micromachines · 2019Article
- Oxygen consumption in human, tissue-engineered myobundles during basal and electrical stimulation conditions.APL bioengineering · 2019Article
- 3D Bioprinting in Skeletal Muscle Tissue Engineering.Small (Weinheim an der Bergstrasse, Germany) · 2019Review
- Functional regeneration of tissue engineered skeletal muscle in vitro is dependent on the inclusion of basement membrane proteins.Cytoskeleton (Hoboken, N.J.) · 2019Article
- Platelet-like particles dynamically stiffen fibrin matrices and improve wound healing outcomes.Biomaterials science · 2019Article
- Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies.Therapeutic advances in neurological disorders · 2019Review
- Scalable 3D Printed Molds for Human Tissue Engineered Skeletal Muscle.Frontiers in bioengineering and biotechnology · 2019Article
- A Novel Microplate 3D Bioprinting Platform for the Engineering of Muscle and Tendon Tissues.SLAS technology · 2018Article
- A real-time monitoring platform of myogenesis regulators using double fluorescent labeling.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Tissue engineering for in vitro drug-screening applications based on tissue function is an active area of translational research. Compared to targeted high-throughput drug-screening methods that rapidly analyze hundreds of thousands of compounds affecting a single biochemical reaction or gene expression, high-content screening (HCS) with engineered tissues is more complex and based on the cumulative positive and negative effects of a compound on the multiple pathways altering tissue function. It may therefore serve as better predictor of in vivo activity and serve as a bridge between high-throughput drug screening and in vivo animal studies. In the case of the musculoskeletal system, tissue function includes determining improvements in the mechanical properties of bone, tendon, cartilage, and, for skeletal muscle, contractile properties such as rate of contraction/relaxation, force generation, fatigability, and recovery from fatigue. HCS of compound banks with engineered tissues requires miniature musculoskeletal organs as well as automated functional testing. The resulting technologies should be rapid, cost effective, and reduce the number of small animals required for follow-on in vivo studies. Identification of compounds that improve the repair/regeneration of damaged tissues in vivo would have extensive clinical applications for treating musculoskeletal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.